In this podcast, our correspondent Dr Rachel Giles covers 5 presentations held at the European Heart Rhythm Association (EHRA), held 23-25 April 2021. The topics discussed are:
- Svennberg E. Benefits of systematic screening for atrial fibrillation – the STROKESTOP study.
- Rienstra M. Targeted therapy of underlying conditions in patients with persistent atrial fibrillation and mild to moderate stable heart failure: long-term outcome of the RACE 3 Trial.
- Pavlović N. Impact of initial rhythm control with cryoballoon ablation versus drug therapy on atrial fibrillation recurrence and quality of life: results from the Cryo-FIRST study.
- Lambiase P. Long-term efficacy and final outcomes of the subcutaneous implantable cardioverter-defibrillator registry.
- Singh J. How to treat cardiac resynchronisation therapy non-responders?
Posted on
Table of Contents: EHRA 2021
Featured articles
Atrial Fibrillation and Direct Oral Anticoagulant
Predictors of young-onset atrial fibrillation
RACE 3 long-term results show fading benefit of targeted therapies in AF and HF
Deep dive into EAST-AFNET 4 results on early rhythm-control in atrial fibrillation
Cryo-FIRST study: improved AF and QoL outcomes with cryoballoon versus drug therapy
STROKESTOP: Benefits of systematic screening for atrial fibrillation
DOACs and bleeding: the role of antidotes
2021 EHRA practical guide: DOACs in pre-operative and bleeding patients
Atrial Ablation
Early rhythm-control ablation: insight from the CHARISMA registry
Personalised pulmonary vein isolation procedure feasible and effective
Pulmonary vein isolation: cryoballoon non-inferior to radiofrequency ablation
Diagnostic Tools
EHRA Practical Guide on cardiac imaging in electrophysiology
Novel diagnostic score accurately differentiates between athlete’s heart and ARVC
The precordial R-prime wave: a discriminator between cardiac sarcoidosis and ARVC
Limited added value of ECG-based mortality prediction in COVID-19 patients using machine learning
Devices
EHRA expert statement on pacemakers and intracardial devices: “watch out for the little old lady”
5-Year efficacy of subcutaneous implantable cardioverter defibrillator
Specific Populations
Individualised approaches key to success in resynchronisation therapy non-responders
Antiarrhythmic drug treatment in children: evidence-based recommendations
The importance of cardiac imaging in patients with congenital heart disease
site created by:
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy